• 作者：José ; Moreno-Arribas ; ^{jmorarr@gmail.com} ; Vicente Bertomeu-Gonzá ; lez ; Alberto Cordero ; Vicente Bertomeu-Martí ; nez
• 关键词：Fibrilació ; n auricular ; Ictus ; Anticoagulantes orales ; Antagonistas de la vitamina K ; Dabigatrá ; n
• 刊名：Revista Espa?ola de Cardiolog¡§aa Suplementos
• 出版年：2012
• 出版时间：2012
• 年：2012
• 卷：12
• 期：supp_S2
• 页码：37-43
• 全文大小：183 K

For many years, treatment with vitamin K antagonists has been the only therapeutic option for preventing embolic events in patients with atrial fibrillation. Recently, a number of other possibilities have become available with the introduction of new oral anticoagulants, which have been shown to be safe and effective in these patients. Their main advantages are that they do not require regular monitoring and they exhibit few interactions with other drugs or with food. This article summarizes the main indications for these new oral anticoagulants, with a particular emphasis on dabigatran, which is currently the only one of these new drugs that has been approved by the Spanish Medicines Agency for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.